title: Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
abstract: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), recently received FDA approval for recurrent glioblastoma. Additionally, several VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have entered trials for recurrent glioma. Phase II studies of bevacizumab for recurrent GBM have reported incidents of ischemic stroke (IS) and intracranial hemorrhage (ICH); however, their clinical features and outcomes were not described in detail. We conducted a retrospective study of recurrent malignant glioma patients with radiographically-confirmed IS or ICH while on antiangiogenic therapy. The study population included patients treated between 2005 and 2010 at the National Cancer Institute on four different phase I and II trials of antiangiogenic agents for recurrent malignant glioma, as well as patients receiving bevacizumab off clinical trial during this same period. Eight patients developed IS (50% lacunar) and 14 experienced ICH (79% intratumoral) while on antiangiogenic therapy for malignant glioma recurrence. The median age was 53 years, 17 patients (77%) were men, and 59% had glioblastoma. The frequencies of IS and ICH were 1.9% and 1.9% in bevacizumab trials. None of the patients on VEGFR TKI trials developed IS, while 3.8% experienced ICH. Patients with IS were treated with antiangiogenic agents longer than those with ICH (median, 16.2 vs. 2.6 months, P = 0.001). Median survival was 7.8 months after IS and 2.6 months after ICH. The most common IS subtype was lacunar, while most ICHs were asymptomatic and intratumoral. Overall, IS seems to be a complication of prolonged antiangiogenic therapy, while intratumoral bleeds often occur in the setting of tumor progression.
authors: Neuro-Oncology Branch, National Cancer Institute and National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9030 Old Georgetown Rd., Bethesda, MD 20892-8202, USA. tyler.fraum@duke.edu
authors: Tyler J
authors: TJ
authors: Fraum
authors: Teri N
authors: TN
authors: Kreisl
authors: Joohee
authors: J
authors: Sul
authors: Howard A
authors: HA
authors: Fine
authors: Fabio M
authors: FM
authors: Iwamoto
references: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references: 19720927
references: Neuro Oncol. 2008 Aug;10(4):624-30
references: 18539884
references: J Neurooncol. 2009 Jan;91(2):175-82
references: 18797818
references: Neurology. 2010 Feb 9;74(6):494-501
references: 20142616
references: J Clin Oncol. 2011 Jan 10;29(2):142-8
references: 21135282
references: Neuro Oncol. 2010 Jan;12(1):95-103
references: 20150372
references: Invest New Drugs. 2005 Aug;23(4):357-61
references: 16012795
references: Neuro Oncol. 2006 Apr;8(2):189-93
references: 16533878
references: J Clin Oncol. 2009 Feb 10;27(5):740-5
references: 19114704
references: J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
references: 17686822
references: J Clin Oncol. 2009 Oct 10;27(29):4865-73
references: 19704059
references: Clin Cancer Res. 2006 Aug 15;12(16):4899-907
references: 16914578
references: Neuro Oncol. 2011 May;13(5):509-16
references: 21377994
references: Oncology. 2010;79(1-2):27-38
references: 21051914
references: Neuro Oncol. 2010 Aug;12(8):855-61
references: 20200024
references: J Clin Oncol. 2010 Feb 20;28(6):e91-3
references: 19933906
references: Circulation. 2007 Feb 6;115(5):e69-171
references: 17194875
references: Neuro Oncol. 2009 Oct;11(5):550-5
references: 19332770
references: Br J Cancer. 2007 Jun 18;96(12):1788-95
references: 17519900
references: J Neurooncol. 2010 Aug;99(1):49-56
references: 20035366
references: J Clin Oncol. 2004 Nov 1;22(21):4282-9
references: 15514370
references: Arch Neurol. 2004 Mar;61(3):362-5
references: 15023812
references: Nat Rev Neurol. 2009 Nov;5(11):610-20
references: 19826401
references: Neurology. 2008 Jun 10;70(24):2314-20
references: 18541885
references: J Clin Oncol. 2006 Aug 1;24(22):3651-6
references: 16877733
references: Haemostasis. 1992;22(2):99-103
references: 1379970